Page 4 - Breakthrough Designation News Today

SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today

The Center for Drug Evaluation, of the National Medical Products Administration in China, has granted a breakthrough therapy designation to savolitinib for use in patients with locally advanced or metastatic gastric cancer or gastroesophageal junction with MET amplification in whom at least 2 lines of standard therapy have failed.

/PRNewswire/ -- Recently, magAssists NyokAssist™ Interventional Ventricular Assist Device (hereinafter referred to as NyokAssist™), has been granted...

Capital raise closed in July, led by new healthcare investors; provides access to up to $26.3 million in capital, with $10 million immediately available AcelRx...

VenoStent Completes $16M Series A Financing, Receives IDE Approval ...

Orthopedic surgeon Ken Zaslav, MD, performed the first commercial case with CartiHeals Agili-C in the U.S., the medtech company said July 26.

The Advanced Wound Management Market encompasses a range of sophisticated products and therapies designed to accelerate the healing process and optimize wound care. These solutions go beyond traditional wound dressings, incorporating advanced materials, specialized devices, and novel treatment modalities that promot...

June 29, 2023News release BioPorto Announces Submission of Response to FDA Additional Information Letter COPENHAGEN, DENMARK and BOSTON, MA, June 29,...

FinancialContent fully hosted finance channel

The Hawaii Senate has approved a bill to create an advisory council to look into possible regulations to provide access to federal “breakthrough therapies” like psilocybin and MDMA. The legislation from Rep. Adrian Tam (D), which previously moved through the House and has since been amended by Senate committees, passed the full chamber without discussion […]